200 related articles for article (PubMed ID: 26783047)
1. Validation of downregulated microRNAs during osteoclast formation and osteoporosis progression.
Ma Y; Shan Z; Ma J; Wang Q; Chu J; Xu P; Qin A; Fan S
Mol Med Rep; 2016 Mar; 13(3):2273-80. PubMed ID: 26783047
[TBL] [Abstract][Full Text] [Related]
2. Pseudogene PTENP1 sponges miR-214 to regulate the expression of PTEN to modulate osteoclast differentiation and attenuate osteoporosis.
Wang CG; Wang L; Yang T; Su SL; Hu YH; Zhong D
Cytotherapy; 2020 Aug; 22(8):412-423. PubMed ID: 32561161
[TBL] [Abstract][Full Text] [Related]
3. DUSP6 expression is associated with osteoporosis through the regulation of osteoclast differentiation via ERK2/Smad2 signaling.
Zhang B; Yuan P; Xu G; Chen Z; Li Z; Ye H; Wang J; Shi P; Sun X
Cell Death Dis; 2021 Sep; 12(9):825. PubMed ID: 34475393
[TBL] [Abstract][Full Text] [Related]
4. MiRNA-483-5p is involved in the pathogenesis of osteoporosis by promoting osteoclast differentiation.
Li K; Chen S; Cai P; Chen K; Li L; Yang X; Yi J; Luo X; Du Y; Zheng H
Mol Cell Probes; 2020 Feb; 49():101479. PubMed ID: 31706013
[TBL] [Abstract][Full Text] [Related]
5. CircRNA_28313/miR-195a/CSF1 axis modulates osteoclast differentiation to affect OVX-induced bone absorption in mice.
Chen X; Ouyang Z; Shen Y; Liu B; Zhang Q; Wan L; Yin Z; Zhu W; Li S; Peng D
RNA Biol; 2019 Sep; 16(9):1249-1262. PubMed ID: 31204558
[TBL] [Abstract][Full Text] [Related]
6. miR-363-3p is activated by MYB and regulates osteoporosis pathogenesis via PTEN/PI3K/AKT signaling pathway.
Li M; Luo R; Yang W; Zhou Z; Li C
In Vitro Cell Dev Biol Anim; 2019 May; 55(5):376-386. PubMed ID: 31025251
[TBL] [Abstract][Full Text] [Related]
7. The role of microRNAs in osteoclasts and osteoporosis.
Tang P; Xiong Q; Ge W; Zhang L
RNA Biol; 2014; 11(11):1355-63. PubMed ID: 25692234
[TBL] [Abstract][Full Text] [Related]
8. miR-21-5p targets SKP2 to reduce osteoclastogenesis in a mouse model of osteoporosis.
Huang Y; Yang Y; Wang J; Yao S; Yao T; Xu Y; Chen Z; Yuan P; Gao J; Shen S; Ma J
J Biol Chem; 2021; 296():100617. PubMed ID: 33811860
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs in Osteoclastogenesis and Function: Potential Therapeutic Targets for Osteoporosis.
Ji X; Chen X; Yu X
Int J Mol Sci; 2016 Mar; 17(3):349. PubMed ID: 27005616
[TBL] [Abstract][Full Text] [Related]
10. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.
Krzeszinski JY; Wei W; Huynh H; Jin Z; Wang X; Chang TC; Xie XJ; He L; Mangala LS; Lopez-Berestein G; Sood AK; Mendell JT; Wan Y
Nature; 2014 Aug; 512(7515):431-5. PubMed ID: 25043055
[TBL] [Abstract][Full Text] [Related]
11. DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis.
Zhang Y; Su J; Wu S; Teng Y; Yin Z; Guo Y; Li J; Li K; Yao L; Li X
Sci Signal; 2015 Mar; 8(369):ra31. PubMed ID: 25805889
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs and their roles in osteoclast differentiation.
Xia Z; Chen C; Chen P; Xie H; Luo X
Front Med; 2011 Dec; 5(4):414-9. PubMed ID: 22198753
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-17/20a inhibits glucocorticoid-induced osteoclast differentiation and function through targeting RANKL expression in osteoblast cells.
Shi C; Qi J; Huang P; Jiang M; Zhou Q; Zhou H; Kang H; Qian N; Yang Q; Guo L; Deng L
Bone; 2014 Nov; 68():67-75. PubMed ID: 25138550
[TBL] [Abstract][Full Text] [Related]
14. Targeting SAT1 prevents osteoporosis through promoting osteoclast apoptosis.
Jin Z; Xu H; Sun X; Yan B; Wang L
Biomed Pharmacother; 2024 Jun; 175():116732. PubMed ID: 38739990
[TBL] [Abstract][Full Text] [Related]
15. MiR-126-5p regulates osteoclast differentiation and bone resorption in giant cell tumor through inhibition of MMP-13.
Wu Z; Yin H; Liu T; Yan W; Li Z; Chen J; Chen H; Wang T; Jiang Z; Zhou W; Xiao J
Biochem Biophys Res Commun; 2014 Jan; 443(3):944-9. PubMed ID: 24360951
[TBL] [Abstract][Full Text] [Related]
16. MiR-503 regulates osteoclastogenesis via targeting RANK.
Chen C; Cheng P; Xie H; Zhou HD; Wu XP; Liao EY; Luo XH
J Bone Miner Res; 2014 Feb; 29(2):338-47. PubMed ID: 23821519
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling of microRNAs in RAW264.7 cells treated with a combination of tumor necrosis factor alpha and RANKL during osteoclast differentiation.
Kagiya T; Nakamura S
J Periodontal Res; 2013 Jun; 48(3):373-85. PubMed ID: 23078176
[TBL] [Abstract][Full Text] [Related]
18. MiR-124 Attenuates Osteoclastogenic Differentiation of Bone Marrow Monocytes Via Targeting Rab27a.
Tang L; Yin Y; Liu J; Li Z; Lu X
Cell Physiol Biochem; 2017; 43(4):1663-1672. PubMed ID: 29045940
[TBL] [Abstract][Full Text] [Related]
19. Critical role of beta3 integrin in experimental postmenopausal osteoporosis.
Zhao H; Kitaura H; Sands MS; Ross FP; Teitelbaum SL; Novack DV
J Bone Miner Res; 2005 Dec; 20(12):2116-23. PubMed ID: 16294265
[TBL] [Abstract][Full Text] [Related]
20. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis.
Kameda Y; Takahata M; Mikuni S; Shimizu T; Hamano H; Angata T; Hatakeyama S; Kinjo M; Iwasaki N
Bone; 2015 Feb; 71():217-26. PubMed ID: 25460183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
